Locally advanced pancreatic cancer: Where should we go from here?

Journal of Clinical Oncology

Volumn 29, Issue 31, 2011, Pages 4066-4068

  Philip, Agop ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MOLECULAR MARKER; OXALIPLATIN;

ADVANCED CANCER; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CLINICAL PRACTICE; EDITORIAL; HUMAN; LOCALLY ADVANCED PANCREATIC CANCER; MEDICAL LITERATURE; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK BENEFIT ANALYSIS; SURVIVAL TIME; TUMOR SUPPRESSOR GENE; VALIDITY;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; PANCREATIC NEOPLASMS;

EID: 80755181067     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.2532     Document Type: Editorial

References (11)

1. Loehrer PJ Sr, Feng Y, Cardenes H, et al.: Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: An Eastern Cooperative Oncology Group trial. J Clin Oncol 29:4105-4112, 2011
2. Iacobuzio-Donahue CA, Fu B, Yachida S, et al.: DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 27:1806-1813, 2009
3. Klaassen DJ, MacIntyre JM, Catton GE, et al.: Treatment of locally unresectable cancer of the stomach and pancreas: A randomized comparison of 5-flurouracil alone with radiation plus concurrent and maintenance 5-fluorouracil - An Eastern Cooperative Oncology Group Study. J Clin Oncol 3:373-378, 1985 (Pubitemid 15132005)
4. Moertel CG, Frytak S, Hahn RG, et al.: Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-flurouracil - The Gastrointestinal Tumor Study Group. Cancer 48:1705-1710, 1981 (Pubitemid 11022870)
5. Gastrointestinal Tumor Study Group: Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy. J Natl Cancer Inst 80:751-755, 1988
6. Conroy T, Desseigne F, Ychou M, et al.: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364:1817-1825, 2011
7. Huguet F, André T, Hammel P, et al.: Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 25:326-331, 2007 (Pubitemid 350003022)
8. Huguet F, Girard N, Guerche CS, et al.: Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: A qualitative systematic review. J Clin Oncol 27:2269-2277, 2009
9. Crane CH, Varadhachary GR, Yordy JS, et al.: Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4 (Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 29:3037-3043, 2011
10. Jones S, Zhang X, Parsons DW, et al.: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801- 1806, 2008
11. Philip PA, Mooney M, Jaffe D, et al.: Consensus report of the National Cancer Institute Clinical Trials Planning Meeting on pancreas cancer treatment. J Clin Oncol 27:5660-5669, 2009